Browse the evidence

18 participants reduced their weight by an average of 8.6% from baseline after a one-year course focused on coping strategies for low carbohydrate intake.

Practitioners can implement similar group courses focusing on coping strategies for low carbohydrate diets to aid weight loss.

The course is proposed as an easily applicable method to address obesity in specialized settings.

This approach can be integrated into obesity treatment programs in various healthcare settings.

Obesity is a primary driver for the development of type 2 diabetes.

Weight loss interventions should be prioritized in managing patients with type 2 diabetes.

The treatment of obesity includes lifestyle modifications, pharmacological interventions, and surgical procedures.

Practitioners should implement a multifaceted approach to obesity treatment.

Obesity is recognized as a chronic, progressive condition requiring early intervention and long-term management.

Practitioners should prioritize early intervention and long-term strategies in managing obesity.

The main objective of obesity pharmacotherapy is weight loss and weight loss maintenance.

Weight loss medications should be viewed as tools for achieving and maintaining weight loss.

The position statement includes recommendations on the overall management of obesity.

Healthcare providers should utilize these recommendations to improve obesity management.

The treatment of obesity requires a multifaceted approach, including lifestyle interventions, pharmacological treatments, and bariatric surgery.

Practitioners should implement a combination of lifestyle changes, medications, and consider surgical options for effective obesity treatment.

GLP-1 agonists such as liraglutide and semaglutide are more efficacious than other approved drugs in weight management therapy.

Practitioners may consider GLP-1 agonists as a preferred option for weight management in diabetic patients.

Tirzepatide reduces fasting and postprandial glucose levels, food consumption, and body weight in people with type 2 diabetes.

Tirzepatide may be an effective treatment option for managing blood glucose and weight in type 2 diabetes patients.

Body weight decreased by 13.3% in patients treated with semaglutide compared to a marginal decrease of -2.6% in placebo-treated patients (P < .001).

Semaglutide can significantly aid in weight loss for obese patients with heart failure.

Long-acting GLP-1 agonists and incretin multi-agonists have demonstrated clinically significant efficacy in reducing body weight.

Practitioners may consider GLP-1 agonists and incretin multi-agonists as effective options for weight management in obese patients.

Automatic motivation and physical opportunities have direct effects on the duration of resistance training participation among GLP-1 medication users.

Interventions should enhance automatic motivation and ensure physical opportunities to increase resistance training duration.

AOM use prior to BMS is associated with significantly higher weight loss until the day of surgery (1.37 vs. 0.05; p = 0.04).

Practitioners may consider AOMs as a beneficial preoperative strategy for weight loss in bariatric surgery candidates.

GLP-1 based medications can achieve an average weight loss of 24%.

Practitioners can expect significant weight loss with GLP-1 medications.

GLP-1 agonists positively affect multiple obesity-related complications.

GLP-1 agonists can be used to manage various obesity-related health issues.

GLP-1-agonists significantly reduce the risk of cardiovascular endpoints in patients with overweight or obesity without diabetes, with a Number Needed to Treat (NNT) of 44.

GLP-1-agonists may be considered for reducing cardiovascular risk in non-diabetic patients with obesity.

Lifestyle therapies, including weight loss and diet, are effective for managing obesity-related hypertension.

Encouraging weight loss and dietary changes can be beneficial for patients with obesity-related hypertension.

Incretin drug therapy can produce significant weight loss in properly selected individuals.

Clinicians should consider incretin therapy for weight loss in appropriately selected patients.

New dietary interventions are poised to overtake traditional strategies as the ideal approach to achieving sustained weight loss for obesity-associated hypertension patients.

Practitioners should consider implementing new dietary interventions for better weight loss outcomes in patients.

Eine Gewichtsabnahme kann die urogynäkologischen Symptome verbessern, bei 5–10% Gewichtsreduktion wird ein Rückgang der Inkontinenzepisoden bis zu 60% beschrieben.

Gewichtsreduktion sollte als Therapieoption zur Verbesserung urogynäkologischer Symptome in Betracht gezogen werden.

Bariatric surgery is the most effective treatment for obesity, yielding sustainable weight loss of about 20-30%.

Bariatric surgery should be considered for patients with obesity seeking significant weight loss.

GLP-1 receptor agonist semaglutide 2.4 mg and dual GLP-1 and GIP agonist tirzepatide have raised the bar for weight loss efficacy in obesity pharmacotherapies.

Clinicians should consider GLP-1 and GIP agonists as effective options for obesity treatment.

Combinations of GLP-1 RA, GIP, and glucagon RA (retatrutide) have shown weight loss efficacy approaching that of bariatric surgery.

Combination therapies may offer significant weight loss benefits similar to surgical options.